389 related articles for article (PubMed ID: 15157343)
1. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
Liu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
[TBL] [Abstract][Full Text] [Related]
2. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
3. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
[TBL] [Abstract][Full Text] [Related]
4. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
5. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
van den Eynde B
Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
[TBL] [Abstract][Full Text] [Related]
6. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
7. Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy.
Wu J; Wei J; Meng K; Chen J; Gao W; Zhang J; Xu Z; Miao Y
Immunopharmacol Immunotoxicol; 2009; 31(3):468-76. PubMed ID: 19555216
[TBL] [Abstract][Full Text] [Related]
8. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
[TBL] [Abstract][Full Text] [Related]
9. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
11. Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice.
Larsen HL; Andersen MH; Wandall HH; Madsen CB; Christensen RE; Petersen TR; Pedersen AE
Scand J Immunol; 2014 Aug; 80(2):111-20. PubMed ID: 24846184
[TBL] [Abstract][Full Text] [Related]
12. [HLA-restricted cancer-specific killer T cells].
Harada M; Itoh K
Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
[No Abstract] [Full Text] [Related]
13. Molecular pathological approaches to human tumor immunology.
Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T
Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363
[TBL] [Abstract][Full Text] [Related]
14. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG
Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
[TBL] [Abstract][Full Text] [Related]
15. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
16. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
17. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
18. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
19. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; van der Burg SH; Offringa R
Eur J Immunol; 2008 Apr; 38(4):1033-42. PubMed ID: 18350546
[TBL] [Abstract][Full Text] [Related]
20. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
